AKTX Stock Summary and Trading Ideas (Akari Therapeutics PLC - American Depositary Shares | NASDAQ:AKTX)

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.

As of January 2, 2025, AKTX stock price declined to $1.18 with 118,086 million shares trading.

AKTX has a beta of 1.20, meaning it tends to be more sensitive to market movements. AKTX has a correlation of 0.02 to the broad based SPY ETF.

AKTX has a market cap of $31.24 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, AKTX traded as high as $32.20 and as low as $.90.

AKTX has underperformed the market in the last year with a return of -62.2%, while the SPY ETF gained +24.0%. In the last 3 month period, AKTX fell short of the market, returning -60.0%, while SPY returned +1.9%. However, in the most recent 2 weeks AKTX has outperformed the stock market by returning +18.0%, while SPY returned -3.3%.

AKTX support price is $1.11 and resistance is $1.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX shares will trade within this expected range on the day.